The yield on the benchmark 10-year Treasury note fell to its lowest level since September 2017 as the Fed began its two-day policy meeting.Bondsread more
The move is part of a larger trend that saw the survey's 179 participants move away from risk and toward positions that reflect fear of a coming economic slowdown spurred by a...Marketsread more
Shares of Beyond Meat soared 18% in premarket trading Tuesday, surpassing $200 per share.Food & Beverageread more
Investors bracing themselves for lower Federal Reserve rates should think about loading up on health care stocks, history shows.Marketsread more
Trump went after Draghi for opening the door for more monetary stimulus in Europe, which would weaken the euro relative to the dollar.Marketsread more
Private equity billionaire David Rubenstein says he's spoken with U.S. and Chinese officials. "My view is both sides want a deal."Economyread more
The yoga-pants retailer is now selling such personal-care products as face moisturizer, dry shampoo, deodorant and lip balm.Retailread more
Hershey CEO Michele Buck said that the 125-year-old company is monitoring the trend but doesn't have any plans to add CBD to its food just yet.Food & Beverageread more
Netflix clarified the premise of its "Prank Encounters" show starring "Stranger Things" actor Gaten Matarazzo after massive internet backlash. The company said all...Entertainmentread more
The chipmaker crush could persist and investors should be selective, but Nvidia looks like a clear buy, one market watcher says.Trading Nationread more
Restaurants have a hard time hiring and retaining dishwashers, but now there's a robot for that.At Workread more
Allergan said on Wednesday its experimental add-on treatment for depression failed three late-stage studies, casting doubts over its drugs pipeline and sending the Botox-maker's shares down nearly 4 percent after the bell.
The failure comes as the company faces increasing pressure from activist shareholders such as billionaire hedge fund manager David Tepper, who has urged the drugmaker to consider selling itself.
Allergan's shares have been lagging those of its industry peers on account of abandoned plans to sell some businesses, a disappointing 2019 revenue forecast and rising competition for several important drugs.
"We expect greater focus on strategic actions with activist push likely to continue to heighten with the May 1 shareholder meeting approaching shortly," RBC Capital Markets analyst Randall Stanicky said in a note.
Stanicky said the data was the most anticipated release of the year and likely means that Allergan will lose what had been expected to be a $1 billion to $2 billion peak sales opportunity.
Some analysts, however, were not surprised, pointing out that investors had low expectations from the trial.
Allergan said the trials compared rapastinel and placebo, both in combination with antidepressant therapy (ADT) in patients with major depressive disorder who showed a partial response to ADT. The company added that it expected to make a decision on these programs during the course of 2019.
The failure comes just a day after the U.S. Food and Drug Administration approved a Johnson & Johnson nasal spray antidepressant, making it the first new type of treatment for the disorder in more than 30 years.
Analysts had expected rapastinel, a fast-acting intravenous antidepressant, to likely rival the J&J drug, which is a chemical mirror image of anesthetic ketamine.
Allergan bought rapastinel in 2015 from its collaborator Aptinyx and added another depression drug from the company last year.
The trial results highlighted the need for more options for people suffering from depression, with a large number of patients not responding to current treatments and some of the drugs carrying significant side effects.
Depression is a common disorder that currently affects 300 million people of all ages globally, according to the World Health Organization, calling it the leading cause of disability.
An interim analysis of the treatment in a relapse prevention study also indicated that the main goals will not be met, the company said.
Allergan's shares were down 3.5 percent at $132.70.